BOSTON SCIENTIFIC CORP's ticker is BSX and the CUSIP is 101137107. A total of 841 filers reported holding BOSTON SCIENTIFIC CORP in Q3 2022. The put-call ratio across all filers is 1.29 and the average weighting 0.3%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sendero Wealth Management, LLC | 58,144 | $2,252,000 | 0.94% |
| abrdn plc | 7,971,115 | $308,721,000 | 0.92% |
| NS Partners Ltd | 358,871 | $13,899,000 | 0.90% |
| BRADLEY FOSTER & SARGENT INC/CT | 835,873 | $32,373,000 | 0.90% |
| SAMLYN CAPITAL, LLC | 1,237,097 | $47,912,000 | 0.89% |
| Ulland Investment Advisors, LLC | 20,666 | $800,000 | 0.87% |
| MARSHALL WACE, LLP | 10,090,359 | $390,798,000 | 0.86% |
| Holocene Advisors, LP | 3,398,887 | $131,639,000 | 0.84% |
| COMMUNITY TRUST & INVESTMENT CO | 223,524 | $8,657,000 | 0.83% |
| ROTHSCHILD & CO ASSET MANAGEMENT US INC. | 1,224,301 | $47,417,000 | 0.81% |
| Gould Capital, LLC | 24,166 | $936,000 | 0.81% |
| KBC Group NV | 3,957,687 | $153,281,000 | 0.80% |
| Concentric Capital Strategies, LP | 58,112 | $2,251,000 | 0.79% |
| Midwest Professional Planners, LTD. | 33,753 | $1,307,000 | 0.78% |
| ASSOCIATED BANC-CORP | 424,287 | $16,432,000 | 0.76% |
| Cinctive Capital Management LP | 456,369 | $17,675,000 | 0.74% |
| LAZARD ASSET MANAGEMENT LLC | 12,539,719 | $485,662,000 | 0.71% |
| D1 Capital Partners L.P. | 1,000,000 | $38,730,000 | 0.71% |
| JANUS HENDERSON GROUP PLC | 48,716,792 | $944,358,415 | 0.71% |
| Ninety One UK Ltd | 5,500,234 | $213,024,000 | 0.70% |
About BOSTON SCIENTIFIC CORP
Boston Scientific Corp is a leading medical device company that specializes in developing innovative medical technologies. The company has a strong presence in the global market and is known for its high-quality products and services. Boston Scientific Corp has a diverse portfolio of products that cater to a wide range of medical needs, including cardiovascular, urology, and endoscopy.
The company has a strong leadership team, with Michael F. Mahoney serving as the CEO and Chairman of the Board. Under his leadership, Boston Scientific Corp has continued to grow and expand its operations. The company has a strong focus on research and development, with a significant portion of its revenue being invested in this area.
Boston Scientific Corp has also been actively involved in mergers and acquisitions, which has helped the company to expand its product portfolio and enter new markets. In 2018, the company acquired NxThera, a medical device company that specializes in treating prostate conditions. This acquisition has helped Boston Scientific Corp to strengthen its position in the urology market.
Overall, Boston Scientific Corp is a strong and reliable company that is well-positioned for future growth. With a strong leadership team, a diverse portfolio of products, and a focus on research and development, the company is poised to continue its success in the global medical device market.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BOSTON SCIENTIFIC CORP's shareholders in Q3 2022. To view BOSTON SCIENTIFIC CORP's shareholder history, click here.